Polio vaccine: Should New Zealand make the change?

New Zealand Medical Journal

Volumn 110, Issue 1051, 1997, Pages 340-342

  Baker, Christina ^a   Eberhart Phillips, Jason ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE;

HEALTH CARE POLICY; INFECTION PREVENTION; NEW ZEALAND; NOTE; POLIOMYELITIS;

CHILD; DISEASE OUTBREAKS; HUMANS; IMMUNIZATION SCHEDULE; NEW ZEALAND; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; PUBLIC OPINION; SEROTYPING;

EID: 0030866470     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (19)

1. Estcourt M, Holdaway D, Lennon D, et al. Poliomyelitis, in: Immunisation handbook. Wellington: Ministry of Health; 1996: p. 82-9.
2. Hull HF, Lee JW. Sabin, Salk or sequential. Lancet 1996; 347: 630.
3. Hull HF, Ward NA, Hull BP, et al. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet 1994; 343: 1331-7.
4. CDC. Certification of poliomyelitis elimination - the Americas, 1994. MMWR 1994; 43: 720-2.
5. CDC. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. MMWR 1997; 46/No. RR-3.
6. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992; 14: 568-79.
7. Beale AJ. Polio vaccines: time for a change in immunization policy. Lancet 1990; 335: 839-42.
8. Bourke J, Roy CW. Paralytic poliomyelitis. NZ Med J 1992; 105: 36-7.
9. Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 1996; 14: 735-46.
10. Hinman AR, Koplan JP, Orenstein WA, et al. Live or inactivated poliomyelitis vaccine: an analysis of benefits and risks. Am J Public Health 1988; 78: 291-5.
11. Judelsohn R. Changing the US polio immunisation schedule would be bad public health policy. Pediatrics 1996; 98: 115-6.
12. Miller MA, Sutter RW, Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA 1996; 276: 967-71.
13. McBean AM, Thomas ML, Albrecht P, et al. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol 1988; 128: 615-28.
14. Faden H, Modlin JF, Thomas ML, et al. Comparative evaluation of immunization with live attenuated and enhanced potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 1990; 162: 1291-7.
15. Onorato IM; Modlin JF, McBean AM, et al. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991; 163: 1-6.
16. Schaap GJP, Bijkerk H, Coutinho RA, et al. The spread of wild poliovirus in the well-vaccinated Netherlands in connection with the 1978 epidemic. Prog Med Virol 1984; 29: 124-40.
17. Oostvogel PM, van Wijngaarden JK, van der Avoort HGAM, et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93. Lancet 1994; 344: 665-70.
18. Immunisation coverage in New Zealand. Comm Dis NZ 1992; 92 (Suppl 2): 1-22.
19. Hovi T, Cantell K, Huovilainen A, et al. Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1986; 1427-32.